Reivindicaciones

1. - A compound of formula (I): <img class="EMIRef" id="0bceabdc-aaf2-43c3-9ff5-744c78e57579-ib0007" /> wherein: - R<1> is selected from among hydrogen, linear or branched C<1>-C<4> alkyl, phenylalkyl of less than 10 carbon atoms and -COCH<3>; - R<2> is selected from among hydrogen, -COCH<3> and -SO<3>Y; - R<3> is selected from among hydrogen, linear or branched C<1>-C<4> alkyl, phenylalkyl of less than 10 carbon atoms,-COCH<3> and -COPh, where Ph is phenyl; - G is selected from among -COOR<4> and -COOY; - A and B are selected, independently from each other, from among hydrogen, -SO<3>H,-SO<3>Y and -COCH<3>; wherein necessarily A or B is either -SO<3>H, or -SO<3>Y, R<4> is selected from among hydrogen, C<1>-C<2> alkyl and arylalkyl of less than 16 carbon atoms, and Y is an organic or inorganic cation; or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of neuropathic pain. 2. - The compound for use according to claim 1, characterized in that: - R<1> is selected from among hydrogen and linear C<1>-C<4> alkyl, and - G is selected from among -COOR<4> and -COOY, wherein R<4> is hydrogen or C<1>-C<2> alkyl and Y is an inorganic cation. 3. - The compound for use according to claim 2, characterized in that R<1> is hydrogen, R<2> is -COCH<3> and R<3> is hydrogen. 4. - The compound for use according to claim 2, characterized in that R<1> is methyl, R<2> is -COCH<3> and R<3> is hydrogen. 5. - The compound for use according to any of claims 3 or 4, characterized in that A is hydrogen, B is -SO<3>Y and G is -COOY, wherein Y is an inorganic cation. 6. - The compound for use according to any of claims 3 or 4, characterized in that A is -SO<3>Y, B is hydrogen, and G is -COOY, wherein Y is an inorganic cation. 7. - The compound for use according to any of claims 3 or 4, characterized in that A and B are-SOsY and G is -COOY, wherein Y is an inorganic cation. 8. - The compound for use according to claim 1, characterized in that the compound of formula (I) is chosen from among the group made up of the following compounds: <img class="EMIRef" id="0bceabdc-aaf2-43c3-9ff5-744c78e57579-ib0008" /> <img class="EMIRef" id="0bceabdc-aaf2-43c3-9ff5-744c78e57579-ib0009" /> and <img class="EMIRef" id="0bceabdc-aaf2-43c3-9ff5-744c78e57579-ib0010" /> 9. - The compound for use according to claim 1, characterized in that the compound of formula (I) is: <img class="EMIRef" id="0bceabdc-aaf2-43c3-9ff5-744c78e57579-ib0011" /> 10. - The compound for use according to any of claims 1 to 9, characterized in that the neuropathic pain is chosen from among: diabetic neuropathy, postherpetic neuralgia, neuropathy induced by chemotherapy, HIV-related neuropathy, rheumatoid arthritis-related neuropathy, osteoarthritis-related neuropathy, fibromyalgia-related neuropathy, trigeminal neuralgia, glossopharyngeal neuralgia, sphenopalatine ganglion neuralgia, vidian nerve neuralgia, persistent idiopathic facial pain, primary atypical facial neuralgia, pain related to phantom limbs, cerebral vascular post-accident pain, post-surgical pain syndrome, pain from multiple sclerosis and pain from spinal cord injuries. 11. - The compound for use according to claim 10, characterized in that the neuropathic pain is chosen from among: diabetic neuropathy, postherpetic neuralgia, neuropathy induced by chemotherapy and fibromyalgia-related neuropathy. 12. - The compound for use according to any of claims 1 to 11, characterized in that the treatment of the neuropathic pain relates to reversing or preventing the symptoms of mechanical allodynia or cold allodynia. 13. - A pharmaceutical composition comprising a compound of formula (I), as defined in any of claims 1 to 9, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient, for use in the treatment of neuropathic pain.